New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 9, 2014
08:41 EDTGILD, ESRXAttack on Gilead Sovaldi by Express Scripts 'noise,' says Maxim
After Bloomberg reported that Express Scripts (ESRX) said that it would attempt to build a coalition against the use of Gilead's (GILD) Sovaldi once a rival drug is approved, Maxim views Express Scripts' statement as "noise." The firm says that Sovaldi is not the most expensive HCV drug, and reiterates its view that Sovaldi provides "compelling" value, when including the cost of failure rates in a cost/benefit analysis. Maxim keeps a Buy rating on Gilead.
News For GILD;ESRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 13, 2014
13:29 EDTGILDLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:26 EDTGILDLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including Leukemia/MDS on an Analyst/Industry conference call to be held on November 20 at 10 am.
November 12, 2014
07:53 EDTGILDLeerink to hold a tour
Subscribe for More Information
November 11, 2014
16:14 EDTGILDLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including JAK inhibitors, novel Jakafi combinations for Myelofibrosis and developing compounds on an Analyst/Industry conference call to be held on November 17 at 10 am.
16:01 EDTGILDOptions Update; November 11, 2014
Subscribe for More Information
11:35 EDTGILDUBS holds a conference call with Gilead Sciences
UBS Biotech Analyst Roden, along with Dr. Bischofberger of Gilead Sciences, discuss the recently-held AASLD Meeting and the outlook of several GILD pipeline programs on a conference call to be held on November 13 at 4:30 pm.
08:07 EDTGILDGilead announces results from Phase 2 and 3 studies evaluating Harvoni
Subscribe for More Information
08:05 EDTGILDGilead announces data from Phase 2 Sofosbuvir plus GS-5816 studies
Subscribe for More Information
November 10, 2014
16:00 EDTGILDOptions Update; November 10, 2014
Subscribe for More Information
09:35 EDTGILDActive equity options trading
Subscribe for More Information
09:20 EDTGILDOn The Fly: Pre-market Movers
Subscribe for More Information
08:48 EDTGILDGilead rises after Merck presents data on HCV combo
Subscribe for More Information
07:20 EDTGILDGilead overhang from Merck HCV combo removed, says Wells Fargo
Subscribe for More Information
November 7, 2014
09:36 EDTGILDActive equity options trading
Active equity options trading according to Track Data: AAPL WFM ABX GILD TSLA ZNGA FB FSLR GOOG AMZN
07:43 EDTGILDGilead Harvoni prescriptions trending well above Sovaldi, says RBC Capital
Subscribe for More Information
November 6, 2014
16:00 EDTGILDOptions Update; November 6, 2014
Subscribe for More Information
15:13 EDTGILDAmerican Association for Study of Liver Diseases to hold a meeting
Subscribe for More Information
12:20 EDTGILDStocks with call strike movement; RIG GILD
Transocean (RIG) February 33 call option implied volatility decreased 7% to 42, Gilead (GILD) May 130 call option implied volatility increased 2% to 38 according to IVolatility.
09:40 EDTGILDActive equity options trading
Subscribe for More Information
08:39 EDTGILDGilead submits NDA to FDA for elvitegravir, emtricitabine, tenofovir alafenamid
Gilead Sciences announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration for an investigational, once-daily single tablet regimen containing elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg for the treatment of HIV-1 infection in adults. The data submitted in the NDA support the use of the regimen among adult and adolescent treatment-na´ve HIV individuals, virologically suppressed patients who switch regimens and those with renal impairment. Gilead plans to submit a regulatory application for E/C/F/TAF in the European Union by the end of 2014.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use